



PRISM



GENE FORUM

DECEMBER 4-6 | PARIS, FRANCE

2ND INTERNATIONAL CONFERENCE ON HUMAN GENE THERAPY

DECEMBER 04, 05, 06, 2024

Cité Internationale Universitaire de Paris, France



www.genetherapyconference.com

Opening Speech

Time Zone: Paris **Re-Engineering and Rewriting Genetics with Gene therapy: Past, Present & Future Approaches**

13:00–13:30
12:00–12:30 (GMT) **Title: Issues and Crisis Management–Staving off Disastrous Consequences: Preparedness and Strategic Approaches**
Tristan Jervis, Impact Shine Communications, UK

13:30–14:00 **Title: TBA**
Adrien Clavairolly, AdBio Partners, France

14:00–14:40 **Title: Gene Therapies for Rare Diseases: Facing Obstacles and Limitations**
Antoni Matilla-Dueñas, Biointaxis, Spain

14:30–15:00
13:30–14:00 (GMT) **Title: Next Generation of Programmable, Intuitive, Vectors for Clinical Applications of Gene Therapy.**
Farzin Farzaneh, ViroCell Biologics, UK

15:00–15:30 **BREAK**

15:30–16:00
09:30–10:00 (EST) **Title: International Enrollment in Gene Therapy Clinical Trials: Strategies and Challenges**
Chrissy Burton & Alicia M. Gomez, BridgeBio, USA

16:00–16:30
10:00–10:30 (EST) **Title: AAV Safety and the Need for Better Data Sharing in Gene Therapy Clinical Trials**
Genevieve Laforet, Aspa Therapeutics, USA

16:30–17:00
10:30–11:00 (EST) **Title: TBA**
Mitra Tavakkoli, Senior Biotech Consultant, USA

17:00–17:30
11:00– 11:30 (EST) **Title: TBA**
Megan Sutton, LEXEO Therapeutics, USA

17:30–18:00
11:30–12:00 (EST) **Title: TBA**
Arun Srivatsava, University of Florida College of Medicine, USA

Gene Therapeutics: Clinical Approaches and Applications

- 12:20-12:30
08:20-08:30 (JST) Title: gBoost™, a Cell-Selective Gene Expression Enhancer (E-Poster)
Mak Inoue, Infirmacea Inc, Japan
- 12:30-13:00 Title: CAR-Tregs Therapies to Treat Immunological Disorders
Sophie Blondel, Taegia, France
- 13:00-13:30 Title: CNS Gene Therapy : Recent Advances and Challenges.
Nathalie Cartier, Asklepios BioPharmaceutical, France
- 13:30-14:00 Title: New Strategies for Allogeneic Cellular Immunotherapies
Olivier Negre, Smart Immune, France
- 14:00-14:30 BREAK
- 14:30-15:00 Title: Scaling New Heights in the Fight Against Heart Disease
Natasha Paterson, Tenaya Therapeutics
- 15:00-15:30
14:00-14:30 (GMT) Title: Advancing Gene Therapeutics into GMP Compliant Commercial Manufacturing
James Drinkwater, Franz Ziel GmbH, UK
- 15:30-16:00
09:30-10:00 (EST) Title: Prime Editing Permits to Correct Point Mutations Responsible for Many Muscular Dystrophies
Jacques P. Tremblay, Laval University, Canada
- 16:00-16:30
07:00-07:30 (PST) Title: FDA Regulations
Binh Nguyen, Wynngate Corporation, USA
- 16:30-17:00 Title: The Role of Regulatory CMC in the Development of a GT
Gabriel Bohl, ICON Plc, France

Unlocking Health Mysteries: Analytics, Manufacturing and Commercialization of Strategies

- 14:00-14:30
Title: Dual AAV Manufacturing & Control Strategy
Christine Le Bec, Sensorion, France
- 14:30-15:00
Title: Lessons Learned from 2 Decades of GT Using AAV as a Therapeutic Modality: Key Elements to Consider Promoting Successful Development
Anne Douar, Vivet Therapeutics, France
- 15:00-15:30
Title: Translate Core Technologies into Pioneering Manufacturing Technologies to Accelerate the Time-To-Market for Gene Therapies
Pascale Berthet, CELL'ECTIV Consulting, France
- 15:30-16:00
14:30-15:00 (GMT)
Title: Digital Twins and AI to Support Real Time Batch Manufacturing.
Shayoni Dutta, GSK, UK
- 16:00-16:30
10:00-10:30 (EST)
Title: Navigating US Market Access: 3 Things you must get right.
Jeff Chaffin, Miles Payer Strategy, USA